IL33 and heart failure: Consequently, sST2 release dampens the beneficial IL-33/ST2L axis, shifts the immune response from a Th2 (anti-inflammatory) to a Th1 (proinflammatory) profile, and promotes cell death, fibrosis, and progression of heart failure [3,22,25].